See more : Musk Metals Corp. (MUSK.CN) Income Statement Analysis – Financial Results
Complete financial analysis of Tiziana Life Sciences Ltd (TLSA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tiziana Life Sciences Ltd, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Bunker Hill Mining Corp. (BHLL) Income Statement Analysis – Financial Results
- Prithvi Exchange (India) Limited (PRITHVIEXCH.BO) Income Statement Analysis – Financial Results
- 8i Acquisition 2 Corp. (LAXXU) Income Statement Analysis – Financial Results
- Volt Power Group Limited (VPR.AX) Income Statement Analysis – Financial Results
- Lotus Bakeries NV (0F4O.L) Income Statement Analysis – Financial Results
Tiziana Life Sciences Ltd (TLSA)
About Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00K | 0.00 | -82.00K | 0.00 | 56.00K | 92.00K | 64.00K | 405.00K | 116.00K | 99.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.00K | 20.00K | 24.00K | 209.00K | 40.00K | 45.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00K | 0.00 | -82.00K | 0.00 | 45.00K | 72.00K | 40.00K | 196.00K | 76.00K | 54.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 100.00% | 0.00% | 80.36% | 78.26% | 62.50% | 48.40% | 65.52% | 54.55% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 8.11M | 12.96M | 13.21M | 5.99M | 2.91M | 4.34M | 4.67M | 2.96M | 6.29M | 794.00K | 0.00 | 0.00 | 0.00 | 0.00 | 80.00K | 412.00K | 737.00K | 826.00K | 745.00K | 457.00K | 326.00K | 580.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 855.00K | 13.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 286.00K | 458.00K | 207.00K | 0.00 | 719.00K | 1.18M | 1.53M | 1.67M | 0.00 | 0.00 | 0.00 | 1.29M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 0.00 | 855.00K | 13.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 286.00K | 458.00K | 207.00K | 0.00 | 719.00K | 1.18M | 1.53M | 1.67M | 0.00 | 0.00 | 0.00 | 1.29M | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 9.87M | 1.63M | 13.31M | 8.82M | 4.86M | 3.48M | 3.57M | 4.33M | 2.33M | 1.97M | 0.00 | 0.00 | 82.00K | -3.03M | -9.00K | -2.00K | 63.00K | 0.00 | 1.50M | 1.06M | 218.00K | 451.00K | 2.42M | 2.43M | 488.00K | 199.00K |
| Operating Expenses | 17.98M | 14.59M | 27.37M | 30.04M | 7.77M | 7.82M | 8.25M | 7.29M | 8.61M | 2.76M | 286.00K | 458.00K | 289.00K | -3.03M | 790.00K | 1.59M | 2.33M | 2.50M | 2.24M | 1.52M | 544.00K | 2.32M | 2.42M | 2.43M | 488.00K | 199.00K |
| Cost & Expenses | 17.98M | 14.59M | 27.37M | 28.03M | 7.77M | 7.82M | 8.25M | 7.29M | 8.61M | 2.76M | 286.00K | 458.00K | 289.00K | -3.03M | 801.00K | 1.61M | 2.35M | 2.71M | 2.28M | 1.57M | 544.00K | 2.32M | 2.42M | 2.43M | 488.00K | 199.00K |
| Interest Income | 1.15M | 0.00 | 0.00 | 8.00K | 1.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.00K | 56.00K | 36.00K | 47.00K | 47.00K | 10.00K | 22.00K | 79.00K | 157.00K | 8.00K | 1.00K |
| Interest Expense | 10.00K | 7.00K | 176.00K | 320.00K | 73.00K | 9.46K | 9.00K | 9.00K | 18.00K | 14.00K | 0.00 | 0.00 | 0.00 | 0.00 | 4.00K | 3.00K | 5.00K | 8.00K | 10.00K | 5.00K | 8.00K | 2.00K | 4.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 96.00K | 51.00K | 141.00K | 89.76K | 198.00K | 12.61K | 11.00K | 8.00K | 0.00 | -794.00K | 3.00K | -195.00K | -489.00K | 0.00 | 238.00K | 300.00K | 59.00K | 133.00K | 33.00K | 20.00K | 32.00K | 21.00K | 20.00K | 25.00K | 1.00K | 1.00K |
| EBITDA | -17.14M | -15.34M | -26.34M | -27.93M | -7.58M | -7.81M | -8.24M | -7.28M | -8.61M | -3.56M | -283.00K | -653.00K | -778.00K | -3.03M | -516.00K | -1.24M | -2.49M | -2.15M | -2.18M | -1.48M | -1.95M | -2.35M | -2.39M | -2.33M | -553.00K | -271.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -9,433.33% | 0.00% | 948.78% | 0.00% | -921.43% | -1,348.91% | -3,890.63% | -531.60% | -1,879.31% | -1,491.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -17.98M | -14.59M | -27.37M | -28.03M | -7.77M | -7.82M | -8.25M | -7.29M | -8.61M | -2.76M | -286.00K | -458.00K | -289.00K | -3.03M | -754.00K | -1.54M | -2.55M | -2.29M | -2.21M | -1.50M | -1.98M | -2.37M | -2.41M | -2.35M | -554.00K | -272.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -9,533.33% | 0.00% | 352.44% | 0.00% | -1,346.43% | -1,675.00% | -3,982.81% | -564.44% | -1,907.76% | -1,512.12% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 742.00K | -811.00K | 717.00K | -312.00K | -73.00K | -8.67K | -9.00K | -9.00K | -18.00K | -808.00K | 3.00K | -195.00K | 0.00 | 0.00 | -4.00K | 31.00K | -37.00K | -8.00K | -10.00K | -5.00K | -8.00K | -2.00K | -4.00K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -17.24M | -15.40M | -26.66M | -28.34M | -7.85M | -7.83M | -8.26M | -7.30M | -8.63M | -3.57M | -283.00K | -653.00K | -289.00K | 0.00 | -758.00K | -1.51M | -2.59M | -2.29M | -2.22M | -1.50M | -1.99M | -2.37M | -2.41M | -2.35M | -554.00K | -272.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -9,433.33% | 0.00% | 352.44% | 0.00% | -1,353.57% | -1,641.30% | -4,040.63% | -566.42% | -1,916.38% | -1,517.17% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 449.00K | 0.00 | -3.24M | -2.21M | -540.00K | -1.53M | -1.49M | -89.00K | 0.00 | -60.00K | -3.00K | 195.00K | 489.00K | 3.03M | -28.00K | -81.00K | -169.00K | -118.00K | -82.00K | -114.00K | -30.00K | -65.00K | -89.00K | -83.00K | 0.00 | 0.00 |
| Net Income | -17.69M | -15.40M | -23.42M | -26.13M | -7.31M | -6.30M | -6.77M | -7.21M | -8.63M | -3.51M | -280.00K | -848.00K | -778.00K | -3.03M | -730.00K | -1.43M | -2.42M | -2.18M | -2.14M | -1.39M | -1.96M | -2.31M | -2.33M | -2.27M | -554.00K | -272.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -9,333.33% | 0.00% | 948.78% | 0.00% | -1,303.57% | -1,553.26% | -3,776.56% | -537.28% | -1,845.69% | -1,402.02% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.00 | -0.15 | -0.24 | -0.27 | -0.05 | -0.10 | -0.13 | -0.15 | -0.19 | -0.31 | 0.00 | 0.00 | 0.00 | -0.10 | -0.05 | -0.24 | -0.52 | -0.01 | -0.01 | -0.01 | -0.02 | -0.06 | -0.09 | -0.09 | -0.02 | -0.01 |
| EPS Diluted | 0.00 | -0.15 | -0.24 | -0.27 | -0.05 | -0.10 | -0.13 | -0.15 | -0.19 | -0.31 | 0.00 | 0.00 | 0.00 | -0.10 | -0.05 | -0.24 | -0.52 | -0.01 | -0.01 | -0.01 | -0.02 | -0.06 | -0.09 | -0.09 | -0.02 | -0.01 |
| Weighted Avg Shares Out | 0.00 | 101.53M | 97.93M | 97.31M | 136.48M | 63.78M | 53.20M | 46.80M | 45.62M | 11.43M | 273.43M | 214.38M | 179.12M | 31.08M | 13.67M | 5.96M | 4.64M | 297.60M | 191.67M | 140.37M | 100.40M | 37.75M | 25.07M | 24.09M | 25.77M | 25.77M |
| Weighted Avg Shares Out (Dil) | 0.00 | 101.53M | 97.93M | 97.31M | 136.48M | 63.78M | 53.20M | 46.80M | 45.62M | 11.43M | 273.43M | 214.38M | 179.12M | 31.08M | 13.67M | 5.96M | 4.64M | 297.60M | 191.67M | 140.37M | 100.40M | 37.75M | 25.07M | 24.09M | 25.77M | 25.77M |
Tiziana Life Sciences to present new imaging data for lead asset at upcoming neurology conference
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it will be presenting new data about its lead clinical asset foralumab at the Annual Meeting of the American Academy of Neurology being held from April 13 to 18 in Denver, Colorado. The...
Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced an upcoming oral presentation, titled, “Treatment of PIRA with Nasal Foralumab Dampens Microglial...
Tiziana Life Sciences to present positive data for lead drug candidate in Alzheimer's disease
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that chairman of its Scientific Advisory Board Dr. Howard Weiner will present positive data on intranasal anti-CD3 monoclonal antibody (mAb) in models of Alzheimer's and Parkinson's disease at an upcoming conference.
Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer's Disease
NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced that Dr. Howard Weiner will present positive data of intranasal anti-CD3 monoclonal antibody in...
Tiziana Life Sciences reveals positive clinical, PET scan findings for intranasal Foralumab in MS patients
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that positive findings have been seen in a total of six out of eight Intermediate Size Patient Population Expanded Access (EA) patients, which have shown improvements in fatigue scores measured by the Modified Fatigue...
Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients
NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced positive findings have been seen in a total of six out of eight Intermediate...
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024
NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that its Chief Operating Officer and Chief Medical Officer, Matthew Davis, MD, RPh, will...
Tiziana Life Sciences files patent for foralumab combination therapy for obesity-associated inflammation
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has filed a new patent application relating to the composition and methods for combining a GLP-1 receptor agonist (ra) and foralumab, its lead drug candidate, to further reduce system and vascular inflammation...
Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation
NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced filing of a new patent application relating to composition and methods for combining GLP-1ra...
Tiziana Life Sciences doses first patient in mid-stage multiple sclerosis study
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that the first patient has been dosed in its Phase 2a study which is comparing two doses of its investigational therapeutic intranasal foralumab and placebo in patients with non-active secondary-progressive multiple sclerosis (na-SPMS). The...
Source: https://incomestatements.info
Category: Stock Reports